Qiang Xu

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Menghua Dai · 2 shared papers, 2021–2025 · strength 0.33
   • Paper Development and validation of a nomogram model based on ultrasound and contrast-enhanced ultrasound features for differ… DOI 10.1007/s00261-025-05035-2↗
   • Paper Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma. DOI 10.2147/cmar.s307079↗
2. Yuejuan Cheng · 2 shared papers, 2021–2025 · strength 0.29
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
   • Paper Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma. DOI 10.2147/cmar.s307079↗
3. Yuxin Jiang · 1 shared paper, 2025 · strength 0.22
   • Paper Development and validation of a nomogram model based on ultrasound and contrast-enhanced ultrasound features for differ… DOI 10.1007/s00261-025-05035-2↗
4. Junchao Guo · 1 shared paper, 2025 · strength 0.22
   • Paper Development and validation of a nomogram model based on ultrasound and contrast-enhanced ultrasound features for differ… DOI 10.1007/s00261-025-05035-2↗
5. Hua Liang · 1 shared paper, 2025 · strength 0.22
   • Paper Development and validation of a nomogram model based on ultrasound and contrast-enhanced ultrasound features for differ… DOI 10.1007/s00261-025-05035-2↗
6. Ke Lv · 1 shared paper, 2025 · strength 0.22
   • Paper Development and validation of a nomogram model based on ultrasound and contrast-enhanced ultrasound features for differ… DOI 10.1007/s00261-025-05035-2↗
7. Weibin Wang · 1 shared paper, 2025 · strength 0.22
   • Paper Development and validation of a nomogram model based on ultrasound and contrast-enhanced ultrasound features for differ… DOI 10.1007/s00261-025-05035-2↗
8. Huan Wang · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
9. Xue Yang · 1 shared paper, 2025 · strength 0.18
   • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
10. Xiaoyu Yin · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
11. Tongsen Zheng · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
12. Xianze Wang · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
13. Chuntao Gao · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
14. Zhihua Li · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
15. Tao Xia · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
16. Heshui Wu · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
17. Rufu Chen · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
18. Deliang Fu · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
19. Wenming Wu · 1 shared paper, 2025 · strength 0.18
    • Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
20. Ke Lv · 1 shared paper, 2021 · strength 0.10
    • Paper Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma. DOI 10.2147/cmar.s307079↗
21. Tongtong Zhou · 1 shared paper, 2021 · strength 0.10
    • Paper Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma. DOI 10.2147/cmar.s307079↗
22. Yuxin Jiang · 1 shared paper, 2021 · strength 0.10
    • Paper Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma. DOI 10.2147/cmar.s307079↗
23. Chunmei Bai · 1 shared paper, 2021 · strength 0.10
    • Paper Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma. DOI 10.2147/cmar.s307079↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.